DOI: 10.1097/mnm.0000000000001803 ISSN: 0143-3636

68Ga-Pentixafor PET/CT for in-vivo mapping of CXCR4 receptors as potential radiotheranostic targets in soft tissue and bone sarcoma: preliminary results

Santosh Ranjan Jena, Ankit Watts, Piyush Aggarwal, Vikas Bachhal, Harneet Kaur, Kirti Dhingra, Harmandeep Singh, Amanjit Bal, Baljinder Singh
  • Radiology, Nuclear Medicine and imaging
  • General Medicine

Objective

To evaluate the diagnostic utility of 68Ga-Pentixafor PET/CT for in vivo imaging of CXCR4 receptors in soft tissue/bone sarcoma.

Methods

Ten (7M: 3F; mean age = 24.7 ± 14.2 years) consecutive patients with clinical and radiological evidence of bone/soft tissue sarcoma were recruited prospectively whole body 68Ga-Pentixafor PET/CT imaging was performed at 60-min after tracer administration. After performing standard CT, PET acquisition from head to toe was done (3 min/bed position) in a caudocranial direction. PET/CT data was reconstructed and SUVmax, SUVmean values, target-to-background ratio (TBR) and active tumor volume (cc) were computed for the tracer avid lesions. Histopathological and IHC analysis was performed on the surgically excised primary tumors. CXCR4 receptors’ intensity was evaluated by visual scoring.

Results

The mean SUVmax and SUVmean values in the primary tumors were 4.80 ± 1.0 (3.9–7.7) and 2.40 ± 0.60 (0.9–4.0). The mean TBR and tumor volume (cc) were 1.84 ± 1.3 and 312.2 ± 285. Diagnosis of osteosarcoma in 7, chondrosarcoma, leiomyosarcoma and synovial sarcoma in 1 patient each was confirmed on HP analysis. Distant metastatic lesions were seen in 3/10 patients. Nuclear CXCR4 receptors’ positivity was seen in 5, cytoplasmic in 4 and both pattern seen in 1 patient. The mean CXCR4 receptors’ intensity was found to be 7.6 ± 2. The highest SUVmax value of 7.7 was observed in the patient having both cytoplasmic and nuclear CXCR4 expression. SUVmax was found to be poorly correlated (r = 0.441) with CXCR4 expression.

Conclusion

68Ga-Pentixafor PET/CT detects CXCR4 receptors over-expressed in sarcoma, its radio-theranostics potential needs detailed evaluation.

More from our Archive